Fintech PR

Halifax Agrees to Acquire the Worldwide Home Care Division of Sodexo

Published

7 months ago

September 29, 2023

WASHINGTON, Sept. 29, 2023 /PRNewswire/ — The Halifax Group (“Halifax“), a middle market private equity firm that partners with management to invest in market-leading companies, announced today that it has agreed to acquire the Worldwide Home Care division of Sodexo, (the “Company”), including their home care subsidiaries in the U.S., U.K., Ireland, France, Denmark, Norway, Sweden and Brazil.

“We are thrilled to partner with a company whose mission we support so wholeheartedly,” said Scott Plumridge, Managing Partner at Halifax. “In the U.S., we have tracked and admired the Comfort Keepers brand for a long time, and it is a privilege to have this opportunity to support the continued expansion of the Company’s global collection of brands. The Company and its franchisees play an important role in helping individuals to live independently in the comfort of their own homes. The Company is one of the largest operators in this sizeable market and has distinguished itself through the high-quality professional care that brings personal interaction, dignity, and joy to seniors as they age in place.”

The Company provides in-home care services across eight countries. Headquartered in Irvine, California, the Company operates as a franchisor in the U.S. in the non-medical personal care sector with 535 franchised territories and 105 company-owned territories. Internationally, the Company offers personal care in Ireland, the U.K., Norway, Denmark, Sweden, and France. In addition, it offers complex care (skilled nursing, therapies and home hospitalization) in the U.K. and Brazil. The Worldwide Home Care Division CEO Natalie Black will remain at the Company along with the senior management team.

Sophie Bellon, Chairwoman and CEO of Sodexo, said, “We are pleased to have reached an agreement with Halifax, and confident that their resources and expertise will greatly benefit the Worldwide Home Care team in accelerating their growth and success. For Sodexo, this milestone marks another step forward in the implementation of our 2025 strategic plan, and our ambition to become the leader in sustainable food and valued experiences.”

Molly Fitzpatrick, Vice President at Halifax, said, “We look forward to working with the leadership team to build on the Company’s impressive market position and accelerate its growth. Halifax has a long history of investing in home care services as well as franchisors, and we understand the advantages for all stakeholders of providing these care services in the lower-cost and comfortable home setting.”

Natalie Black, CEO of the Worldwide Home Care Division of Sodexo, said, “We have enjoyed remarkable achievements over the last 15 years, having grown our footprint to more than 700 locations around the world. We are now pleased to work with Halifax, whose financial resources and experience with both home care services and the franchise model will be invaluable as we prepare for the future. Along with our franchisees and dedicated care providers, we will continue to enhance our service offerings and deliver excellent service to more clients and families.”

Halifax has a history of supporting leading home healthcare and franchising companies, including Caring Brands International, another leading franchisor of home healthcare services. In partnership with management, Halifax grew the U.S.-based Interim HealthCare through both organic initiatives and acquisitions, adding U.K.-based Bluebird Care and Australia-based Just Better Care to form Caring Brands International in 2013. When Halifax sold its stake in the business in 2015, it offered a full continuum of home health services in more than 530 locations in seven countries.

The transaction is expected to close in the fourth quarter of 2023 and is subject to the satisfaction of customary closing conditions. Terms of the transaction were not disclosed. Lazard served as the financial advisor to Sodexo.

About the Worldwide Home Care Division of Sodexo
Sodexo entered the home care market in 2009 with the acquisition of Comfort Keepers in the US and expanded its activities internationally since. The Worldwide Home Care division of Sodexo operates in 8 countries: the US through Comfort Keepers; the United Kingdom through Prestige Home care, The Good Care Group, and Oxford Aunts; Ireland through Comfort Keepers; France through Amelis; Brazil through Pronep, and multiple brands in the Nordics. The Home Care division employs 12,000 people across its locations and are highly recognized for their outstanding care and service, as well as the strong commitments as an employer, in line with the values of Sodexo Group.

About The Halifax Group
Founded in 1999, The Halifax Group is a private equity firm that partners with managers and entrepreneurs to recapitalize and invest in lower middle-market businesses with total enterprise values generally between $100 million and $300 million. Halifax specializes in equity recapitalizations, corporate carve-outs, and management buyouts and invests across a variety of industries, including health and wellness, outsourced business services, and franchising. The firm is headquartered in Washington, D.C. and maintains an office in Raleigh, NC. For more information, please visit www.thehalifaxgroup.com.

About Sodexo
Founded in Marseille in 1966 by Pierre Bellon, Sodexo is the global leader in sustainable food and valued experiences at every moment in life: learn, work, heal and play. Operating in 53 countries, our 422,000 employees serve 100 million consumers each day. The Sodexo Group stands out for its independence and its founding family shareholding, its responsible business model and its portfolio of activities including Food Services, Facilities Management Services and Employee Benefit Solutions. This diversified offer meets all the challenges of everyday life with a dual goal: to improve the quality of life of our employees and those we serve, and contribute to the economic, social and environmental progress in the communities where we operate. For Sodexo, growth and social commitment go hand in hand. Our purpose is to create a better everyday for everyone to build a better life for all. Sodexo is included in the CAC Next 20, CAC 40 ESG, CAC SBT 1.5, FTSE 4 Good and DJSI indices.

Contact:
Lambert
Caroline Luz
203-570-6462
[email protected]

View original content:https://www.prnewswire.co.uk/news-releases/halifax-agrees-to-acquire-the-worldwide-home-care-division-of-sodexo-301942491.html

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

4 weeks ago

April 5, 2024

CISION (PR Newswire)

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf	Invitation to presentation of EQT AB’s Q1 Announcement 2024
https://news.cision.com/eqt/i/eqt-ab-group,c3285895	EQT AB Group

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

4 weeks ago

April 5, 2024

CISION (PR Newswire)

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs

Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

4 weeks ago

April 5, 2024

CISION (PR Newswire)

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html